Investors sold shares of Thermo Fisher Scientific Inc. (NYSE:TMO) on strength during trading on Tuesday. $57.78 million flowed into the stock on the tick-up and $122.75 million flowed out of the stock on the tick-down, for a money net flow of $64.97 million out of the stock. Of all stocks tracked, Thermo Fisher Scientific had the 33rd highest net out-flow for the day. Thermo Fisher Scientific traded up $0.60 for the day and closed at $254.92

TMO has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research report on Monday, November 19th. BTIG Research increased their target price on shares of Thermo Fisher Scientific to $290.00 and gave the stock a “buy” rating in a report on Thursday, January 31st. Finally, Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $264.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 30th. Three analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $275.70.

The firm has a market capitalization of $104.21 billion, a P/E ratio of 23.51, a PEG ratio of 1.68 and a beta of 1.13. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.23 and a current ratio of 1.73.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, January 30th. The medical research company reported $3.25 EPS for the quarter, topping analysts’ consensus estimates of $3.19 by $0.06. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.26 billion. Thermo Fisher Scientific had a net margin of 12.06% and a return on equity of 16.86%. The business’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.79 earnings per share. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 12.14 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 16th. Stockholders of record on Friday, March 15th will be issued a $0.19 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.29%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. Thermo Fisher Scientific’s dividend payout ratio is 6.12%.

In other news, insider Gregory J. Herrema sold 3,299 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $263.05, for a total value of $867,801.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $266.00, for a total transaction of $665,000.00. The disclosure for this sale can be found here. Insiders sold 36,927 shares of company stock valued at $9,388,124 in the last three months. Company insiders own 0.49% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Archford Capital Strategies LLC increased its stake in shares of Thermo Fisher Scientific by 0.9% in the fourth quarter. Archford Capital Strategies LLC now owns 4,610 shares of the medical research company’s stock valued at $1,032,000 after buying an additional 43 shares during the period. Aries Wealth Management increased its position in Thermo Fisher Scientific by 1.1% during the 4th quarter. Aries Wealth Management now owns 4,269 shares of the medical research company’s stock valued at $955,000 after purchasing an additional 45 shares during the period. Balasa Dinverno & Foltz LLC increased its position in Thermo Fisher Scientific by 2.1% during the 4th quarter. Balasa Dinverno & Foltz LLC now owns 2,238 shares of the medical research company’s stock valued at $501,000 after purchasing an additional 46 shares during the period. Atlas Capital Advisors LLC increased its position in Thermo Fisher Scientific by 5.5% during the 4th quarter. Atlas Capital Advisors LLC now owns 923 shares of the medical research company’s stock valued at $207,000 after purchasing an additional 48 shares during the period. Finally, Johnson Financial Group Inc. increased its position in Thermo Fisher Scientific by 8.0% during the 4th quarter. Johnson Financial Group Inc. now owns 673 shares of the medical research company’s stock valued at $151,000 after purchasing an additional 50 shares during the period. 87.11% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2019/03/14/investors-sell-thermo-fisher-scientific-tmo-on-strength-tmo.html.

About Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Recommended Story: Buy-Side Analysts

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.